| Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia AE Tron, MA Belmonte, A Adam, BM Aquila, LH Boise, E Chiarparin, ... Nature communications 9 (1), 5341, 2018 | 504 | 2018 |
| Mosunetuzumab induces complete remissions in poor prognosis non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T … SJ Schuster, NL Bartlett, S Assouline, SS Yoon, F Bosch, LH Sehn, ... Blood 134, 6, 2019 | 213 | 2019 |
| CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo GP Gregory, SJ Hogg, LM Kats, E Vidacs, AJ Baker, O Gilan, M Lefebure, ... Leukemia 29 (6), 1437-1441, 2015 | 156 | 2015 |
| The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer SJ Vervoort, SA Welsh, JR Devlin, E Barbieri, DA Knight, S Offley, ... Cell 184 (12), 3143-3162. e32, 2021 | 152 | 2021 |
| CDK13 cooperates with CDK12 to control global RNA polymerase II processivity Z Fan, JR Devlin, SJ Hogg, MA Doyle, PF Harrison, I Todorovski, ... Science advances 6 (18), eaaz5041, 2020 | 139 | 2020 |
| The CDK9 inhibitor dinaciclib exerts potent apoptotic and antitumor effects in preclinical models of MLL-rearranged acute myeloid leukemia A Baker, GP Gregory, I Verbrugge, L Kats, JJ Hilton, E Vidacs, EM Lee, ... Cancer research 76 (5), 1158-1169, 2016 | 124 | 2016 |
| Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition SJ Hogg, O Motorna, LA Cluse, TM Johanson, HD Coughlan, R Raviram, ... Molecular cell 81 (10), 2183-2200. e13, 2021 | 101 | 2021 |
| Rituximab is associated with improved survival for aggressive B cell CNS lymphoma G Gregory, A Arumugaswamy, T Leung, KL Chan, M Abikhair, C Tam, ... Neuro-oncology 15 (8), 1068-1073, 2013 | 82 | 2013 |
| A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies DC Phillips, S Jin, GP Gregory, Q Zhang, J Xue, X Zhao, J Chen, Y Tong, ... Leukemia 34 (6), 1646-1657, 2020 | 81 | 2020 |
| Bispecific antibodies: a review of development, clinical efficacy and toxicity in B-cell lymphomas R Salvaris, J Ong, GP Gregory Journal of Personalized Medicine 11 (5), 355, 2021 | 75 | 2021 |
| BET inhibition induces apoptosis in aggressive B-cell lymphoma via epigenetic regulation of BCL-2 family members SJ Hogg, A Newbold, SJ Vervoort, LA Cluse, BP Martin, GP Gregory, ... Molecular cancer therapeutics 15 (9), 2030-2041, 2016 | 75 | 2016 |
| Mosunetuzumab shows promising efficacy in patients with multiply relapsed follicular lymphoma: updated clinical experience from a phase I dose-escalation trial SE Assouline, WS Kim, LH Sehn, SJ Schuster, CY Cheah, LJ Nastoupil, ... Blood 136, 42-44, 2020 | 66 | 2020 |
| Bcor loss perturbs myeloid differentiation and promotes leukaemogenesis MJ Kelly, J So, AJ Rogers, G Gregory, J Li, M Zethoven, MD Gearhart, ... Nature communications 10 (1), 1347, 2019 | 66 | 2019 |
| AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia SB Balachander, SW Criscione, KF Byth, J Cidado, A Adam, P Lewis, ... Clinical Cancer Research 26 (24), 6535-6549, 2020 | 57 | 2020 |
| Serine biosynthesis is a metabolic vulnerability in flt3-itd–driven acute myeloid leukemia S Bjelosevic, E Gruber, A Newbold, C Shembrey, JR Devlin, SJ Hogg, ... Cancer discovery 11 (6), 1582-1599, 2021 | 53 | 2021 |
| Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma NL Bartlett, S Assouline, P Giri, SJ Schuster, CY Cheah, M Matasar, ... Blood advances 7 (17), 4926-4935, 2023 | 51 | 2023 |
| Genomic characterisation of Eμ-Myc mouse lymphomas identifies Bcor as a Myc co-operative tumour-suppressor gene M Lefebure, RW Tothill, E Kruse, ED Hawkins, J Shortt, GM Matthews, ... Nature communications 8 (1), 14581, 2017 | 50 | 2017 |
| Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic P Di Ciaccio, G McCaughan, J Trotman, PJ Ho, CY Cheah, ... Internal Medicine Journal 50 (6), 667-679, 2020 | 49 | 2020 |
| A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML LM Kats, SJ Vervoort, R Cole, AJ Rogers, GP Gregory, E Vidacs, J Li, ... Leukemia 31 (6), 1466-1470, 2017 | 37 | 2017 |
| Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B‐cell lymphoma are dictated by the CNS disease: a collaborative study of the … JC Wight, M Yue, C Keane, A Johnston, K Linton, C Chin, SH Wai, ... British journal of haematology 187 (2), 174-184, 2019 | 33 | 2019 |
